ClinicalTrials.gg
RecruitingNCT07135050Updated Nov 12, 2026

Phase 1/2 Study of MZ-1866, an AAV-9 Gene Therapy Delivered by Intracerebroventricular Injection to Participants With Pitt Hopkins Syndrome

A Phase 1/2 interventional study of MZ-1866 in Pitt Hopkins Syndrome, sponsored by Mahzi Therapeutics. Recruiting at 4 sites in 2 countries. Open to participants aged 2 Years to 25 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Mahzi Therapeutics · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Nov 12, 20261 site added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
2 Years to 25 Years
Sex
All
01

Study summary

The goal of this clinical trial is to learn if MZ-1866 is a safe and tolerable treatment for children and adults with Pitt Hopkins Syndrome.

To evaluate the safety of MZ-1866, the following will be evaluated:

  • frequency and severity of adverse events
  • physical exam, laboratory results and electrocardiogram findings

Participants will:

  • receive a single dose of MZ-1866 by intracerebroventricular injection
  • be seen by the study physician and site staff periodically to assess changes to their health status
  • be periodically evaluated using neurodevelopmental tools

Caregivers will:

  • be interviewed periodically about the health status and development of the participant
  • keep diaries and complete periodic questionnaires regarding participant symptoms
02

Conditions studied

  • Pitt Hopkins Syndrome

Keywords

  • MZ-1866
  • AAV9 Gene Therapy
  • Gene Therapy
  • ICV
  • Intracerebroventricular
  • TCF4
  • PTHS
03

In context

Lead sponsor

This is the only study on the registry with Mahzi Therapeutics as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant has a TCF4 gene mutation confirmed as "pathogenic" or "likely pathogenic" by whole exome sequencing, whole genome sequencing, gene panel, single gene testing, or microarray, performed at an accredited laboratory
  • Clinical phenotype consistent with Pitt Hopkins Syndrome, in the opinion of the investigator
  • The participant, or the participant's parent or legal guardian, is willing to provide access to prior medical records for the collection of demographics and diagnostic and treatment history

Exclusion criteria

Exclusion Criteria:

  • A deletion that includes the TCF4 gene that is over 12 Mbp in size
  • Another genetic mutation or clinical comorbidity not associated with Pitt Hopkins Syndrome that could potentially confound interpretation of the study data
  • A central nervous system structural or vascular abnormality that is a to the ICV administration procedure, including but not limited to: signs or symptoms of increased intracranial pressure, history of a space-occupying lesion, or presence of a ventricular shunt that would preclude ICV procedures or safety assessments, or increase risk to the participant
  • Not able to receive prophylactic due to a medical contraindication or participant has a history of a condition that could worsen with corticosteroid therapy as assessed and determined by the Investigator
  • Not able to undergo MRI procedures
  • Cannot be anesthetized for the ICV injection
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Cohort 1 (MZ-1866)

    Participants ages 12-25 years

    Genetic: MZ-1866

  • Experimental
    Cohort 2 (MZ-1866)

    Participants aged 2-11 years

    Genetic: MZ-1866

Interventions

  • GeneticMZ-1866

    AAV-9 gene therapy delivered by intracerebroventricular injection

06

What researchers measure

Primary outcomes

  1. To evaluate the safety and tolerability of MZ-1866 in participants with Pitt Hopkins Syndrome

    Frequency and severity of adverse events of special interest

    Time frame: Week 104

Secondary outcomes

  1. To evaluate the safety and tolerability of MZ-1866 in participants with Pitt Hopkins Syndrome

    Frequency and severity of adverse events

    Time frame: Week 104

  2. To further assess the safety and tolerability of MZ-1866 in participants with Pitt Hopkins Syndrome

    Frequency of clinically significant physical examination findings, vital signs, laboratory tests and electrocardiograms that are considered outside normal range.

    Time frame: Week 104

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Mar 2029, 39 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2025
First posted
Aug 21, 2025
StartActual
Dec 19, 2025
Primary completionEst.
Mar 2029
CompletionEst.
Jul 2029
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Sheba Medical Center · Tel HaShomer, Israel
Show 1 removed
  • Sheba Medical Center · Tel Litwinsky, Israel
Nov 12, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Children's Hospital Colorado · Aurora, United StatesContact s•••@childrenscolorado.org→M•••@childrenscolorado.org · •••4166
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    1 site added, 1 site removed
    Show site
    • Sheba Medical Center · Tel HaShomer, Israel
    Show 1 removed
    • Sheba Medical Center · Tel Litwinsky, Israel
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Children's Hospital Colorado · Aurora, United StatesContact s•••@childrenscolorado.org→M•••@childrenscolorado.org · •••4166
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07135050
Lead sponsor
Mahzi Therapeutics
Collaborators
California Institute for Regenerative Medicine (CIRM)
Responsible party
Sponsor
First posted
Aug 21, 2025
Start date
Dec 19, 2025
Primary completion
Mar 2029 (estimated)
Completion
Jul 2029 (estimated)
Last update
Nov 12, 2026

Study contacts

Emily Radomile
Contact
clinicaltrials@mahzi.com
1-844-446-2494

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion